Core Viewpoint - A class action lawsuit has been filed against Zenas BioPharma, Inc. for violations of federal securities laws related to misleading statements made during its IPO [1][4]. Group 1: Lawsuit Details - The lawsuit is initiated by the Schall Law Firm, which specializes in shareholder rights litigation [1][5]. - Investors who purchased Zenas securities during its IPO on September 13, 2024, are encouraged to contact the firm before June 16, 2025, to discuss their rights [2][3]. Group 2: Allegations Against Zenas - The complaint alleges that Zenas made false and misleading statements regarding the sustainability of its operations based on existing cash and expected IPO proceeds [4]. - It is claimed that these misleading statements caused investors to suffer damages once the truth about the company's financial situation was revealed [4].
ZBIO Investors Have Opportunity to Lead Zenas BioPharma, Inc. Securities Fraud Lawsuit with the Schall Law Firm